Lesopitron ( E-4424 ) is a selective 5-HT 1A receptor agonist structurally similar to azapirones. [1] In 2001, it was developed by Esteve as a potential anxiolytic for the treatment of generalized anxiety disorder . [2] [3] Lesopitron passed phase II clinical trials, but its development was discontinued without explanation, and new information has not appeared since. [2] [3]
| Lesopitron | |
|---|---|
 | |
| Chemical compound | |
| IUPAC | 2- {4- [4- (4-chloro-1 H -pyrazol-1-yl) butyl] piperazin-1-yl} pyrimidine |
| Gross formula | C 15 H 21 ClN 6 |
| Molar mass | 320.82 g / mol |
| Cas | |
| PubChem | |
| Drugbank | |
| Classification | |
| Route of administration | |
| Oral | |
See also
- Sunepitron
Notes
- ↑ Haj-Dahmane S., Jolas T., Laporte AM, et al. Interactions of lesopitron (E-4424) with central 5-HT1A receptors: in vitro and in vivo studies in the rat // English Journal of Pharmacology : journal. - 1994 .-- April ( vol. 255 , no. 1-3 ). - P. 185-196 . - DOI : 10.1016 / 0014-2999 (94) 90097-3 . - PMID 8026543 .
- ↑ 1 2 Micheli F. Lesopitron (Esteve) (neopr.) // IDrugs: the Investigational Drugs Journal. - 2001. - February ( t. 4 , No. 2 ). - S. 218-224 . - PMID 16032484 .
- ↑ 1 2 Fresquet A., Sust M., Lloret A., et al. Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder (English) // The Annals of Pharmacotherapy : journal. - 2000 .-- February ( vol. 34 , no. 2 ). - P. 147-153 . - DOI : 10.1345 / aph . 19041 . - PMID 10676820 . (inaccessible link)